AVI BioPharma Announces Third Quarter 2011 Financial Results and Corporate Update Conference Call
October 26 2011 - 8:00AM
Marketwired
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based
therapeutics, will report third quarter 2011 financial results
after the NASDAQ Global Market closes on Thursday, November 3,
2011. Subsequently, at 5:00 p.m., Eastern time (2:00 p.m., Pacific
time), Chris Garabedian, AVI's president and CEO, will host a
conference call to discuss third quarter 2011 financial results and
to provide a corporate update.
The conference call may be accessed by dialing 866.314.5050 for
domestic callers and 617.213.8051 for international callers. The
passcode for the call is 97800942. Please specify to the operator
that you would like to join the "AVI BioPharma third quarter 2011
earnings call." The conference call will be webcast live under the
events section of AVI's website at www.avibio.com and will be
archived there following the call for 90 days. Please connect to
AVI's website several minutes prior to the start of the broadcast
to ensure adequate time for any software download that may be
necessary.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of
novel RNA-based therapeutics for rare and infectious diseases, as
well as other select disease targets. Applying pioneering
technologies developed and optimized by AVI, the Company is able to
target a broad range of diseases and disorders through distinct
RNA-based mechanisms of action. Unlike other RNA-based approaches,
AVI's technologies can be used to directly target both messenger
RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either
down-regulate (inhibit) or up-regulate (promote) the expression of
targeted genes or proteins. By leveraging a highly differentiated
RNA-based technology platform, AVI has built a pipeline of
potentially transformative therapeutic agents, including eteplirsen
(the non-proprietary name for AVI-4658), which is in clinical
development for the treatment of Duchenne muscular dystrophy, and
multiple drug candidates that are in clinical development for the
treatment of infectious diseases. For more information, visit
www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation
Reform Act of 1995: The statements that are not historical facts
contained in this release are forward-looking statements that
involve risks and uncertainties, including, but not limited to, the
results of research and development efforts, the results of
preclinical and clinical testing, the effect of regulation by the
FDA and other agencies, the impact of competitive products, product
development, commercialization and technological difficulties, and
other risks detailed in the company's Securities and Exchange
Commission filings.
AVI Investor and Media Contact: Erin Cox 425.354.5140 Email
Contact
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From May 2024 to Jun 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2023 to Jun 2024